UPDATE ON ROMIPLOSTIM AND ELTROMBOPAG INDIRECT COMPARISON

被引：16

作者：

Cooper, Katy ^{[1
]}

Matcham, James ^{[2
]}

Helme, Kawitha ^{[3
]}

Akehurst, Ron ^{[1
]}

机构：

[1] Univ Sheffield, Sheffield S10 2TN, S Yorkshire, England

[2] Amgen Ltd, Cambridge, England

[3] Amgen Ltd, Uxbridge, Middx, England

来源：

INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE | 2014年 / 30卷 / 01期

关键词：

D O I：

10.1017/S0266462313000767

中图分类号：

R19 [保健组织与事业（卫生事业管理）];

学科分类号：

摘要：

In our article Romiplostim and eltrombopag for immune thrombocytopenia: methods for indirect comparison published in the Journal (1), we presented an indirect comparison of the effectiveness of eltrombopag and romiplostim in raising platelet counts in patients with immune thrombocytopenia (ITP). Indirect comparison analyses are recommended by the National Institute for Health and Care Excellence (NICE) in cases where randomized head-to-head studies do not exist, and were used by NICE in their guidance for the eltrombopag Single Technology Appraisal submission (2). © 2014 Cambridge University Press.

引用

页码：129 / 130

页数：3